Patient specific HA/beta-TCP scaffold were fabricated using an indirect fabrication approach which involves the application of rapid prototyping technology. beta-TCP powder with 10, 20 and 30 % HA concentrations were analyzed for different sintering temperatures. Scaffolds were evaluated by Scanning Electron Microscopy, X-ray diffraction, compression tests, Fourier transform infrared spectroscopy and cytotoxicity tests using human osteosarcoma cell line. Results include HA/beta-TCP scaffold porosity, volumetric shrinkage, mechanical properties, bonding, structural phase change and cytotoxicity.